On December 10, 2025, Representatives Rudy Yakym (R-IN) and André Carson (D-IN) introduced the “Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act of 2025,” a bipartisan effort to protect patients from untested, unapproved, and potentially harmful compounded drugs.
Compounded drugs, often produced in bulk without oversight, have led to over 1,000 adverse event reports, including dangerous dosing errors and unsafe ingredients sourced from unregulated foreign producers. The legislation aims to restore safety and accountability through stronger oversight and transparency. Key provisions include:
- Defines “Essentially a Copy”: Any compounded drug with the same active ingredient as an approved medicine is considered a copy unless a clinically significant change is made for a specific patient.
- Oversight Requirements: 503A compounders must report to the FDA when shipping more than 20 out-of-state prescriptions containing FDA-approved active ingredients. FDA inspections of outsourcing facilities are mandated.
- Enhanced FDA Resources: Increases outsourcing facility user fees to fund timely and regular FDA inspections.
Learn more here.